#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14668	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2065	706.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1462	1462	C	865	C	803	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14668	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2065	706.2	0	HET	.	.	.	A69G	.	69	69	A	347	347	A	877	A,G	693,105	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14668	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2065	706.2	0	HET	.	.	.	C1450T	.	1450	1450	C	1728	1728	C	868	C,T	638,159	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3610	721.7	0	.	n	.	0	T695C	SNP	695	695	T	1044	1044	C	783	C,T	562,164	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3610	721.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1686	1686	A	890	A,G	770,44	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3610	721.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2320	2320	C	834	C	752	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3610	721.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2394	2394	A	831	A	761	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3610	721.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2946	2946	C	787	C,A	729,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	27934	blaTEM	861	861	100.0	blaTEM.l15.c4.ctg.1	1555	1789.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	155	2092	folP	855	855	100.0	folP.l6.c30.ctg.1	1441	144.2	1	SNP	p	R229S	1	.	.	685	687	AGC	979	981	AGC	236;238;235	A,C;G;C	179,37;216;212	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	155	2092	folP	855	855	100.0	folP.l6.c30.ctg.1	1441	144.2	0	HET	.	.	.	C225CGAAGAAGAAGAA,CGAAGAAGAA	.	225	225	C	519	519	C	217	CGAAGAAGAAGAA,CGAAGAAGAA	154,36	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	155	2092	folP	855	855	100.0	folP.l6.c30.ctg.1	1441	144.2	0	HET	.	.	.	T282C,G	.	282	282	T	576	576	T	182	T,C,G	100,26,4	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	667	6296	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3230	194.0	0	.	p	.	0	G95A	NONSYN	283	285	GGC	552	554	GCC	241;233;234	G;C,A,G;C	215;143,47,14;207	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	667	6296	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3230	194.0	1	SNP	p	S91F	1	.	.	271	273	TTC	540	542	TTC	246;243;246	T;T,C;C	222;173,43;218	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	155	1800	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	146.2	1	SNP	p	G45D	0	.	.	133	135	GGC	356	358	GGC	254;253;260	G;G,A;C	230;181,44;234	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	155	1800	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	146.2	0	HET	.	.	.	C90T	.	90	90	C	313	313	C	232	C,T	163,44	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	155	1800	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	146.2	0	HET	.	.	.	G115A	.	115	115	G	338	338	G	246	G,A	172,42	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	155	1800	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	146.2	0	HET	.	.	.	C87G	.	87	87	C	310	310	C	229	C,G	160,45	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	155	1800	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1224	146.2	0	HET	.	.	.	T313C	.	313	313	T	536	536	T	207	T,C	145,50	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	659	754	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1022	73.3	0	.	n	.	0	A197.	DEL	197	197	A	605	605	A	188	A	126	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	659	754	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1022	73.3	0	HET	.	.	.	T193TAAAA,TAAAAA	.	193	193	T	602	602	T	181	TAAAA,TAAAAA	113,44	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	1	SNP	p	D86N	0	.	.	256	258	GAC	699	701	GAC	259;261;259	G;A;C	237;233;237	parC.WHO_X_00208c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	C903T	.	903	903	C	1346	1346	C	220	C,T	162,35	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	T876C	.	876	876	T	1319	1319	T	220	T,C	160,41	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	A1326G	.	1326	1326	A	1769	1769	A	274	A,G	193,54	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	A879G	.	879	879	A	1322	1322	A	220	A,G	165,39	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	T1304C	.	1304	1304	T	1747	1747	T	253	T,C	172,44	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	G1305A	.	1305	1305	G	1748	1748	G	256	G,A	184,48	.	.
parC.WHO_X_00208c	parC.WHO_X_00208c	1	1	155	5886	parC	2304	2304	99.83	parC.l6.c4.ctg.1	3011	194.9	0	HET	.	.	.	A1786G	.	1786	1786	A	2229	2229	A	269	A,G	185,55	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	667	4476	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2736	162.9	0	.	p	.	0	P456S	NONSYN	1366	1368	CCC	1617	1619	TCC	211;212;212	T,C;C;C	141,49;191;191	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	667	4476	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2736	162.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1479	1481	GGC	201;197;197	G;G;C	186;180;181	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	667	4476	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2736	162.9	0	HET	.	.	.	C378T	.	378	378	C	629	629	C	206	C,T	158,25	.	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1279	1281	GCA	237;239;242	G,T,C;C;A	213,1,1;221;223	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1282	1284	ATC	247;246;249	A;T;C	227;225;229	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1294	1296	GTG	253;254;255	G;T;G	235;236;235	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1294	1296	GTG	253;254;255	G;T;G	235;236;235	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1798	1800	ACC	226;226;224	A,G;C;C	191,1;199;197	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1852	1854	GCG	203;204;204	G,A;C,G;G	181,1;166,1;173	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1852	1854	GCG	203;204;204	G,A;C,G;G	181,1;166,1;173	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1975	1977	GGC	174;173;173	G,A;G;C	149,4;143;147	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1984	1986	GGC	171;172;172	G;G;C	145;147;146	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	155	4170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2391	173.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2002	2004	CCG	146;142;147	C,G;C,T;G	100,9;82,18;104	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6088	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2873	210.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1520	1522	CCG	217;220;222	C;C;G	192;203;199	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	659	2566	porA	1146	1146	99.74	porA.l15.c30.ctg.1	1564	161.9	0	.	p	.	0	S22G	NONSYN	64	66	AGC	241	243	GGC	157;161;161	G,A;G;C	103,42;148;146	.	.
porA.NCCP11945	porA.NCCP11945	1	0	659	2566	porA	1146	1146	99.74	porA.l15.c30.ctg.1	1564	161.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	423	423	C	179	C,T	160,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	683	685	AAG	230;229;235	A,G;A,G;G,C,A	174,33;174,33;172,33,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	D121G	NONSYN	361	363	GAC	686	688	GGC	229;229;243	G;G,C,A;C	198;164,33,1;200	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	884	886	CGA	257;252;253	C;G,A;A	233;173,55;227	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	S189N	NONSYN	565	567	AGC	890	892	AAC	252;252;256	A,G;A,G;C	211,14;158,64;229	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	E212D	NONSYN	634	636	GAA	959	961	GAT	251;252;252	G;A;T	225;228;227	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	H213G	NONSYN	637	639	CAT	962	964	GGT	248;247;249	G;G,A;T	225;210,13;225	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	V215A	NONSYN	643	645	GTT	968	970	GCT	247;246;244	G,A;C;T	212,15;225;225	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	I218M	NONSYN	652	654	ATC	977	979	ATG	246;243;241	A;T;G,C,A	225;226;170,51,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1094	1096	ACG	236;231;235	A,T;C,T,G;G	196,11;128,66,11;207	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1100	1102	GTT	226;224;234	G;T,G,C;T	205;130,62,11;211	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1214	1216	AAC	230;228;229	A,T;A;C	211,1;210;210	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	HET	.	.	.	G774C,T	.	774	774	G	1099	1099	G	226	G,C,T	131,63,11	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	HET	.	.	.	A427C	.	427	427	A	752	752	A	235	A,C	151,60	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	667	2900	porB1b	1047	1047	98.38	porB1b.l15.c17.ctg.1	1564	183.3	0	HET	.	.	.	C53T	.	53	53	C	378	378	C	252	C,T	180,49	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	667	10854	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4815	224.9	0	.	p	.	0	G248D	NONSYN	742	744	GGC	1114	1116	GAC	217;214;221	G;A,G;C	204;150,49;205	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	667	10854	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4815	224.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2029	2031	AAT	263;264;266	A,C;A;T	181,63;243;243	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	667	10854	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4815	224.9	0	HET	.	.	.	T3117C	.	3117	3117	T	3489	3489	T	287	T,C	199,62	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	667	10854	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4815	224.9	0	HET	.	.	.	T3042C	.	3042	3042	T	3414	3414	T	231	T,C	157,55	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1122	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	996	111.9	1	SNP	p	V57M	1	.	.	169	171	ATG	519	521	ATG	230;230;231	A;T;G,A	222;221;219,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	10582	tetM	1920	1920	100.0	tetM.l15.c30.ctg.1	2810	375.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
